// App-Quantinova.ai

2124 : Immunological Differences Between PsA Patients Who Are Tumor Necrosis Factor Inhibitor-Naïve and Who Have Inadequate Response to Tumor Necrosis Factor Inhibitors

Researchers

Presenter

  • Atul Deodhar

Principal Investigators

  • Stefan Siebert

  • Laura Coates

  • Georg Schett

  • Siba P. Raychaudhuri

  • Warner Chen

  • Sheng Gao

  • Soumya Chakravarty

  • May Shawi

  • Frederic Lavie

  • Elke Theander

  • Marlies Neuhold

  • Alexa Kollmeier

  • Xie L Xu

  • Proton Rahman

  • Philip J Mease

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences,, Oxford University Hospitals NHS Trust, Oxford, UK, Oxford, United Kingdom

  • Universitatsklinikum Erlangen, Erlangen, Germany

  • Rheumatology, Allergy, and Clinical Immunology, University of California Davis, School of Medicine, Sacramento, CA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, Paris, France

  • Janssen Cilag, Lund, Sweden

  • Janssen, Zug, Switzerland

  • Janssen Research & Development, San Diego, CA

  • Janssen Research & Development, LLC, Spring House, PA/San Diego, Spring House, PA/San Diego, CA

  • Memorial University, St. John's, NF, Canada

  • Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

  • Oregon Health & Science University, Portland, OR, USA, Portland, OR

Locations

  • United Kingdom

  • Germany

  • United States

  • France

  • Sweden

  • Switzerland

  • Canada

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved